COMBINED SSRI-MOCLOBEMIDE TREATMENT OF PSYCHIATRIC-ILLNESS

Background: To determine the efficacy and safety of a serotonin select ive reuptake inhibitor (SSRI) combined with moclobemide in the treatme nt of 11 patients with various DSM-III-R diagnoses. Method: Subjects r eceived moclobemide in doses of 150 to 800 mg/day together with sertra line (N = 5) in doses of 25 to 200 mg/day or fluvoxamine (N = 6) in do ses of 50 to 200 mg/day. Patients were carefully monitored for side ef fects and for clinical response at the end of the trial, which lasted a minimum of 5 weeks. Results: The combination was tolerated extremely well. Insomnia was the most common side effect, occurring in 5 of 11 subjects. A marked or complete therapeutic response was noted in 8 of 11 subjects. Conclusion: This open clinical trial suggests that combin ed SSRI-moclobemide treatment appears to be safe and well tolerated. I t may also have therapeutic effects in treatment-refractory patients.